# A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

> **NCT06990776** · PHASE2 · WITHDRAWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.**

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** TQA3605 tablets Placebo
- **DRUG:** TQA3605 Tablets
- **DRUG:** Entecavir dispersible tablets

## Key facts

- **NCT ID:** NCT06990776
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-07-09
- **Primary completion:** 2025-07-17
- **Final completion:** 2025-07-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06990776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06990776, "A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06990776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*